1. Home
  2. GNPX vs FBGL Comparison

GNPX vs FBGL Comparison

Compare GNPX & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.86

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

FBGL

FBS Global Limited Ordinary Shares

HOLD

Current Price

$0.56

Market Cap

11.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
FBGL
Founded
2009
1996
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Miscellaneous manufacturing industries
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
GNPX
FBGL
Price
$0.86
$0.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
732.3K
128.3K
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.34
52 Week High
$12.97
$1.40

Technical Indicators

Market Signals
Indicator
GNPX
FBGL
Relative Strength Index (RSI) 20.65 41.93
Support Level $0.15 $0.50
Resistance Level $2.12 $0.67
Average True Range (ATR) 0.11 0.04
MACD -0.01 0.00
Stochastic Oscillator 1.25 3.92

Price Performance

Historical Comparison
GNPX
FBGL

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

Share on Social Networks: